Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-β

Journal of Alzheimer's Disease

Volumn 20, Issue 4, 2010, Pages 1119-1132

  Espuny Camacho, Ira ^a,b   Dominguez, Diana ^a,b   Merchiers, Pascal ^c   Van Rompaey, Luc ^c   Selkoe, Dennis ^d   De Strooper, Bart ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GALAPAGOS NV   (Belgium)

^d Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

Amyloid (A ) clearance; insulin degrading enzyme (IDE); metalloprotease; peroxisome proliferator activated receptor gamma (PPAR )

Indexed keywords

1,10 PHENANTHROLINE; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; AMMONIUM CHLORIDE; AMYLOID BETA PROTEIN; ANTIPAIN; BAFILOMYCIN; BENZYLSULFONYL FLUORIDE; CAVEOLIN; CLATHRIN; EDETIC ACID; GLUCAGON; ILOMASTAT; INSULIN; LACTACYSTIN; LEUCINE THIORPHAN; LEUPEPTIN; MATRIX METALLOPROTEINASE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENANTHROLINE; PHOSPHORAMIDON; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; EPITOPE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MEMBRANE PROTEIN; METALLOPROTEINASE; PHENANTHROLINE DERIVATIVE;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CELL CULTURE; CELL MUTANT; CELL SURFACE; CONTROLLED STUDY; EMBRYO; ENDOCYTOSIS; ENZYME ACTIVITY; GEL ELECTROPHORESIS; GLIA CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INSULIN DEGRADATION; LOSS OF FUNCTION MUTATION; MOUSE; NEWBORN; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; WILD TYPE; ANIMAL; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENETICS; GLIA; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMYLOID BETA-PEPTIDES; ANIMALS; BIOTINYLATION; CAVEOLINS; CELLS, CULTURED; CLATHRIN; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOCYTOSIS; EPITOPES; FEMALE; GLUCAGON; INSULYSIN; MEMBRANE PROTEINS; METALLOPROTEASES; MICE; MICE, KNOCKOUT; NEPRILYSIN; NEUROGLIA; NEURONS; PHENANTHROLINES; PLASMIDS; PPAR GAMMA; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 77954556209     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091633     Document Type: Article

References (66)

1. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
2. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22, 2246-2254.
3. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM(2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20, 5709-5714.
4. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal antiinflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23, 9796-9804.
5. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103, 443-448.
6. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
7. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23, 7504-7509.
8. Lleo A, Galea E, Sastre M (2007) Molecular targets of nonsteroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64, 1403-1418.
9. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
10. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13, 950-958.
11. Rabiner EA, Tzimopoulou S, Cunningham VJ, Jeter B, Zvartau-Hind M, Castiglia M, Mistry P, Bird NP, Matthews J, Whitcher B, Nichols TE, Lai R, Lotay N, Saunders A, Reiman E, Chen K, Gold M, Matthews PM (2009) Effects of 1 months of treatment with the PPAR? agonist rosiglitazone on brain glucose metabolism in Alzheimer's Disease: A18F-FDG PET study. Alzheimers Dementia 5, P39-40.
12. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53, 409-435.
13. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloidbeta peptide. J Neurosci 24, 10908-10917.
14. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloidbeta peptide (1-40). J Neurosci 16, 7910-7919.
15. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276, 24540-24548.
16. Howell S, Nalbantoglu J, Crine P (1995) Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16, 647-652.
17. Hu J, Igarashi A, Kamata M, NakagawaH(2001) Angiotensinconverting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
18. Kurochkin IV, Goto S (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345, 33-37.
19. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714.
20. TuckerHM,KihikoM, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20, 3937-3946.
21. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003) Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278, 2081-2084.
22. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
23. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550-1552.
24. Melchor JP, Pawlak R, Strickland S (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abetainduced neurodegeneration. J Neurosci 23, 8867-8871.
25. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 26, 10939-10948.
26. Leissring MA, FarrisW, Chang AY,Walsh DM,Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
27. Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE (2007) Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 282, 7825-7832.
28. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG (2000) Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1, 530-535.
29. Yoshizawa T, Iwamoto H, Mizusawa H, Suzuki N, Matsumoto H, Kanazawa I (1992) Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type. Neuropeptides 22, 85-88.
30. Saido TC, Iwata N (2006) Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 54, 235-253.
31. Saito T, Takaki Y, Iwata N, Trojanowski J, Saido TC (2003) Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ 2003, PE1.
32. Michiels F, van Es H, van Rompaey L, Merchiers P, Francken B, Pittois K, van der Schueren J, Brys R, Vandersmissen J, Beirinckx F, Herman S, Dokic K, Klaassen H, Narinx E, Hagers A, Laenen W, Piest I, Pavliska H, Rombout Y, Langemeijer E, Ma L, Schipper C, Raeymaeker MD, Schweicher S, Jans M, van Beeck K, Tsang IR, van de Stolpe O, Tomme P (2002) Arrayed adenoviral expression libraries for functional screening. Nat Biotechnol 20, 1154-1157.
33. De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG (1995) Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J 14, 4932-4938.
34. Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, Annaert W(2004) Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol 166, 1041-1054.
35. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulindegrading enzyme. J Neurosci 20, 1657-1665.
36. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, AnnaertW, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390.
37. Bradford MM(1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72, 248-254.
38. Chadderton T, Wilson C, Bewick M, Gluck S (1997) Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand) 43, 1227-1234.
39. Altschuler Y, Barbas SM, Terlecky LJ, Tang K, Hardy S, Mostov KE, Schmid SL (1998) Redundant and distinct functions for dynamin-1 and dynamin-2 isoforms. J Cell Biol 143, 1871-1881.
40. Nabi IR, Le PU (2003) Caveolae/raft-dependent endocytosis. J Cell Biol 161, 673-677.
41. Chyung JH, Selkoe DJ (2003) Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem 278, 51035-51043.
42. Daukas G, Zigmond SH (1985) Inhibition of receptormediated but not fluid-phase endocytosis in polymorphonuclear leukocytes. J Cell Biol 101, 1673-1679.
43. Park RD, Sullivan PC, Storrie B (1988) Hypertonic sucrose inhibition of endocytic transport suggests multiple early endocytic compartments. J Cell Physiol 135, 443-450.
44. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160, 101-112.
45. Deane R,Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
46. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382, 716-719.
47. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK (1995) LDL receptorrelated protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82, 331-340.
48. Paresce DM, Ghosh RN, Maxfield FR (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17, 553-565.
49. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031.
50. Santiago-Garcia J, Mas-Oliva J, Innerarity TL, PitasRE(2001) Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J Biol Chem 276, 30655-30661.
51. Husemann J, Loike JD, Kodama T, Silverstein SC (2001) Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol 114, 142-150.
52. Qiu WQ,Walsh DM,Ye Z,Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulindegrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738.
53. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
54. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276, 21895-21901.
55. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C (2004) Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 279, 45519-45527.
56. Yoshisue H, Hasegawa K (2004) Effect of MMP/ADAM inhibitors on goblet cell hyperplasia in cultured human bronchial epithelial cells. Biosci Biotechnol Biochem 68, 2024-2031.
57. Authier F, Posner BI, Bergeron JJ (1996) Insulin-degrading enzyme. Clin Invest Med 19, 149-160.
58. Becker AB, Roth RA (1995) Insulysin and pitrilysin: insulindegrading enzymes of mammals and bacteria. Methods Enzymol 248, 693-703.
59. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19, 608-624.
60. Kurochkin IV (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26, 421-425.
61. Bennett RG, Duckworth WC, Hamel FG (2000) Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275, 36621-36625.
62. Myohanen H, Vaheri A (2004) Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 61, 2840-2858.
63. Chawla A, BoisvertWA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7, 161-171.
64. Costet P, Luo Y, Wang N, Tall AR (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/ retinoid X receptor. J Biol Chem 275, 28240-28245.
65. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ (2000) Regulation of absorption andABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529.
66. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 97, 12097-12102.